Anemia, costs and mortality in chronic obstructive pulmonary disease
- PMID: 17042950
- PMCID: PMC1633732
- DOI: 10.1186/1478-7547-4-17
Anemia, costs and mortality in chronic obstructive pulmonary disease
Abstract
Background: Little is known about cost implications of anemia and its association with mortality in chronic obstructive pulmonary disease (COPD). This claims analysis addresses these questions.
Methods: Using the the US Medicare claims database (1997-2001), this study identified Medicare enrollees with an ICD-9 diagnosis of COPD. Concomitant anemia was identified based on ICD-9 codes or receipt of transfusions. Persons with anemia secondary to another disease state, a nutritional deficiency or a hereditary disease were excluded. Medicare claims and payments, resource utilization and mortality were compared between COPD patients with and without anemia.
Results: Of the 132,424 enrollees with a COPD diagnosis, 21% (n = 27,932) had concomitant anemia. At baseline, anemic patients were older, had more co-morbidities and higher rates of health care resource use than non-anemic individuals with COPD. In a univariate analysis annual Medicare payments for persons with anemia were more than double for those without anemia ($1,466 vs. $649, p < 0.001), the direction maintained in all categories of payments. Adjusting for demographics, co-morbidities, and other markers of disease severity revealed that anemia was independently associated with $3,582 incremental increase per patient (95% CI: $3,299 to $3,865) in Medicare annual reimbursements. The mortality rate among COPD patients with anemia was 262 vs. 133 deaths per 1,000 person-years among those without anemia (p < 0.001).
Conclusion: Anemia was present in 21% of COPD patients. Although more prevalent in more severely ill COPD patients, anemia significantly and independently contributes to the costs of care for COPD and is associated with increased mortality.
Figures



Similar articles
-
Anemia in chronic obstructive pulmonary disease: epidemiology and economic implications.Curr Med Res Opin. 2008 Apr;24(4):1123-30. doi: 10.1185/030079908x280699. Epub 2008 Mar 7. Curr Med Res Opin. 2008. PMID: 18331668
-
Incremental mortality associated with nontuberculous mycobacterial lung disease among US Medicare beneficiaries with chronic obstructive pulmonary disease.BMC Infect Dis. 2023 Nov 1;23(1):749. doi: 10.1186/s12879-023-08689-9. BMC Infect Dis. 2023. PMID: 37914999 Free PMC article.
-
Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis.J Med Econ. 2019 Apr;22(4):319-327. doi: 10.1080/13696998.2018.1563414. Epub 2019 Jan 11. J Med Econ. 2019. PMID: 30580639
-
Anemia in Chronic Obstructive Pulmonary Disease and the Potential Role of Iron Deficiency.COPD. 2016;13(1):100-9. doi: 10.3109/15412555.2015.1043519. Epub 2015 Sep 29. COPD. 2016. PMID: 26418826 Review.
-
Anemia in Chronic obstructive pulmonary disease: Prevalence, pathogenesis, and potential impact.Lung India. 2015 Mar-Apr;32(2):142-51. doi: 10.4103/0970-2113.152626. Lung India. 2015. PMID: 25814799 Free PMC article. Review.
Cited by
-
Economic Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review.Tuberc Respir Dis (Seoul). 2024 Jul;87(3):234-251. doi: 10.4046/trd.2023.0100. Epub 2024 Feb 16. Tuberc Respir Dis (Seoul). 2024. PMID: 38361331 Free PMC article.
-
Use of Laboratory Tests and Their Prognostic Value in Patients with Stable Chronic Obstructive Pulmonary Disease.Mo Med. 2022 Nov-Dec;119(6):545-552. Mo Med. 2022. PMID: 36588649 Free PMC article. Review.
-
Clinical factors and comorbidities affecting the cost of hospital-treated COPD.Int J Chron Obstruct Pulmon Dis. 2016 Dec 2;11:3023-3030. doi: 10.2147/COPD.S120637. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27980399 Free PMC article.
-
[Influence of co-morbidities on the progression and prognosis of patients with chronic obstructive pulmonary disease in a Tunisian Hospital].Pan Afr Med J. 2020 Jun 9;36:76. doi: 10.11604/pamj.2020.36.76.21511. eCollection 2020. Pan Afr Med J. 2020. PMID: 32774635 Free PMC article. French.
-
The attributable annual health costs of U.S. occupational lead poisoning.Int J Occup Environ Health. 2016 Apr;22(2):107-20. doi: 10.1080/10773525.2016.1173945. Epub 2016 May 13. Int J Occup Environ Health. 2016. PMID: 27173488 Free PMC article.
References
-
- Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–1276. - PubMed
-
- National Heart Lung and Blood Institute . Morbidity & Mortality: 2004 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD , National Institutes of Health; 2004.
-
- McCullough PA, Lepor NE. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med. 2005;6 Suppl 3:S4–12. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources